Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Wyze Biotech

Request full access

A biotechnological company

ChinaBiotech & Life Sciences

About Wyze Biotech

Wyze Biotech, officially known as Guangdong Ruishun Biotechnology Co., Ltd., is a biopharmaceutical firm established in 2012, focusing on the clinical development of immune cell therapies. The company was founded in Hangzhou and later relocated its headquarters to Zhongshan, Guangdong, in 2021. Founder and Chairman, Dr. Liming Yang, holds a postdoctoral degree from the University of Toronto's School of Medicine and has three decades of experience in immunology. He is a key inventor of the DNT cell technology that forms the core of the company's research.

The company's primary business involves developing 'off-the-shelf' universal immune cell drugs to treat malignant tumors and autoimmune diseases. Wyze Biotech operates on a business model that encompasses the entire lifecycle of its therapeutic products, from research and development to production and eventual commercialization. Its market consists of patients with critical illnesses, particularly those with conditions like relapsed or refractory acute myeloid leukemia. The company has secured significant funding, raising a total of \$29.9M, with a Series A round in October 2021 bringing in 137 million RMB (approximately \$21.4M), led by Fuho Capital and with participation from investors like Baidu Ventures.

Wyze Biotech's main offering centers on its proprietary Double Negative T (DNT) cell technology platform. DNT cells are a naturally occurring subset of T cells that can be extracted from healthy donors, standardized, and stored for ready use, which helps manage production costs. The company's leading product candidate, RC1012, is an injectable DNT cell therapy. In November 2020, it received investigational new drug (IND) approval from China's National Medical Products Administration to begin clinical trials for treating acute myeloid leukemia. This marked the first non-genetically edited allogeneic T-cell drug to enter registration clinical trials in China. The company is also leveraging its DNT platform by integrating it with CAR-T, gene-editing, and iPSC technologies to develop a pipeline of next-generation cell therapies targeting various blood and solid tumors.

Source: Dealroom company data

At a glance

Status
Operational
Headquarters
China
Employees
2
Open positions
None listed
Dealroom signal
25.9/100
Industry
Health
Sub-industry
BioTechnology
Sector
Biotech & Life Sciences, Biotechnology, Biotech and Pharma, Hard Tech, DT and LS
Business model
Manufacturing
Client focus
B2B

Funding history

2 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES A✓Equity / VC Aug 2022 $9M $108M Undisclosed ↗
SERIES A✓Equity / VC Dec 2021 $22M $86M Undisclosed —
Showing the latest 2 of 2 recorded eventsBook a demo for the full funding history →

Growth signals

Wyze Biotech website traffic

Latest recorded traffic for Wyze Biotech is 5K monthly website visits, up 400% over the last three months. Wyze Biotech's team declined 33.3% over the past year.

Latest monthly visits5K 3-month web change+400% 1-year team growth-33.3%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Wyze Biotech in its local ecosystem

Live from Dealroom

The Wyze Biotech office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Employees 2 total headcount
Founders Hidden — book a demo/100 quality score
Key operators Hidden — book a demo quality score
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
1 countries with
team presence
🇨🇳 China100%
1 country shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Wyze Biotech on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Wyze Biotech’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.